Security key
690469101
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 17,544
- Total 13F value
- $47,193
- Share change
- -210,198
- SEC-reported price per share
- $2.69
- Number of holders
- 1
- Value change
- -$565,428
- Number of sells
- 1
- Shares outstanding
- 186,437,735
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
OVID full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Ovid Therapeutics Inc. SEC filings
Ovid Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 690469101
Recent filing periods:
Ownership snapshot
Top reported holders of OVID - Ovid Therapeutics Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TAKEDA PHARMACEUTICAL CO LTD
Disclosed value leader
Sirenia Capital Managemen...
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 12%
13D/G row: TAKEDA PHARMACEUTICAL CO LTD
Showing 1-6 of 15 holder rows.
Quick read
TAKEDA PHARMACEUTICAL CO LTD leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TAKEDA PHARMACEUTICAL CO LTD's linked filing trail.
Comparable ownership
Top 5
TAKEDA PHARMACEUTICAL CO LTD
12%
JANUS HENDERSON GROUP PLC
10%
Sirenia Capital Management LP
9.9%
RA CAPITAL MANAGEMENT, L.P.
9.9%
Affinity Asset Advisors, LLC
9.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTD |
13D/G
3/4/5
Takeda Pharmaceutical Company Limited · 10%+ Owner
|
12%
|
$11,680,055
8,781,996 shares
|
$0 | 08 Dec 2025 |
| JANUS HENDERSON GROUP PLC |
13F
13D/G
Company
|
10%
from 13D/G
|
$23,731,510
10,714,000 shares
|
— | 31 Mar 2026 |
| Sirenia Capital Management LP |
13D/G
|
9.9%
|
$51,930,239
18,031,333 shares
|
$0 | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$23,785,080
10,714,000 shares
|
— | 31 Mar 2026 |
| Affinity Asset Advisors, LLC |
13D/G
13F
Company
|
9.1%
|
$45,030,194
15,635,484 shares
|
+$10,040,596 | 31 Mar 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13D/G
13F
Company
|
7.3%
|
$36,787,902
12,773,577 shares
|
$0 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
17,544
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
103
Q2 2026 holders
1
Holder diff
-102
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend